× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy


× Important note: This Web site presents preliminary results. We are working non-stop to complete the biocuration as soon as possible.

meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of potential therapies for COVID19

  Summary of results of all meta-analysis  
tutorial video
En     Fr


adjuvant therapies

anticoagulant 2

colchicine

face mask

hydrogen-oxygen nebulizer

hyperbaric oxygen

nintedanib

pulmonary rehabilitation

thalidomide

vitamin C

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies

IFX-1

naproxen, ibuprofen

sodium aescinate

corticosteroids 2

ciclesonide

inhaled steroids

low-dose corticosteroids

imatinib

Immunostimulants drugs

anti-PD-1 antibody

CD24Fc

convalescent plasma treatment

immunoglobulin therapy

emapalumab

inactivated mycobacterium vaccine

Interleukin-2

rhG-CSF

vaccines

Immunosuppressants drugs

anakinra

eculizumab

interleukin-6 inhibitor

clazakizumab

sarilumab

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

siltuximab

tocilizumab

jakotinib

lenzilumab

ruxolitinib

tacrolimus

tetrandrine

leflunomide

pirfenidone

Polyinosinic-Polycytidylic Acid

sargramostim

thymosin

antiviral and associated therapy

ASC09/ritonavir

azithromycin 1

azvudine

baloxavir marboxil

carrimycin

chloroquine and derivatives 5

chloroquine 1

hydroxychloroquine 8

danoprevir / ritonavir

darunavir cobicistat

darunavir/cobicistat plus chloroquine

favipiravir 1

fluvoxamine

hydroxychloroquine plus macrolides 3

interferon

leronlimab

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 2

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b

meplazumab

oseltamivir plus chloroquin

remdesevir 2

Renin-angiotensin-system-acting agents 8

angiotensin receptor blockers (ARBs)

angiotensin-(1-7)

RAS blocker withdrawal

rhACE2

ritonavir

tranexamic acid

triazavirin

umifenovir (arbidol) 1

miscellaneous

acetylcysteine

alpha lipoic acid 1

aviptadil

bevacizumab

bismuth

BLD-2660 (calpain inhibitor)

camostat mesilate

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

dipyridamol

DPP-4 inhibitor

enoxaparin

levamisole

natural killer (NK) cells

nicotin

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

prone positioning

PUL-042 inhalation solution

selinexor

stem cells

tradipitant

tranilast

Latest studies

NIH NIAID ACTT-1 , 2020   NCT04280705 7 days ago

remdesevir vs. placebo some concern in risk of bias

  • suggested 32 % increase in recovery
  • suggested 28 % decrease in serious adverse events
  • inconclusive results for: death

meta-analysis

Mehra , 2020   OBS 8 days ago

hydroxychloroquine plus macrolides vs. control serious risk of bias

  • safety concerns with a 45 % increase in death
  • safety concerns with a 5.1-fold increase in de-novo ventricular arrhythmia

meta-analysis

Mehra , 2020   OBS 8 days ago

chloroquine vs. control serious risk of bias

  • safety concerns with a 37 % increase in death
  • safety concerns with a 3.6-fold increase in de-novo ventricular arrhythmia

meta-analysis

Mehra , 2020   OBS 8 days ago

hydroxychloroquine vs. control serious risk of bias

  • safety concerns with a 34 % increase in death
  • safety concerns with a 2.4-fold increase in de-novo ventricular arrhythmia

meta-analysis

Rosenberg , 2020   OBS 9 days ago

hydroxychloroquine plus macrolides vs. control serious risk of bias

  • safety concerns with a 2.1-fold increase in cardiac arrest
  • inconclusive results for: in hospital mortality; Abnormal ECG findings; Arrhythmia

meta-analysis

Rosenberg , 2020   OBS 9 days ago

hydroxychloroquine vs. control serious risk of bias

  • safety concerns with a 91 % increase in cardiac arrest
  • inconclusive results for: in hospital mortality; Abnormal ECG findings; Arrhythmia

meta-analysis

Rosenberg , 2020   OBS 9 days ago

azithromycin vs. control serious risk of bias

  • inconclusive results for: in hospital mortality; cardiac arrest; Abnormal ECG findings; Arrhythmia

meta-analysis

Geleris , 2020   OBS 3 weeks ago

hydroxychloroquine vs. control serious risk of bias

  • inconclusive results for: intubation or death

meta-analysis

Yu , 2020   OBS 4 weeks ago

hydroxychloroquine vs. control critical risk of bias

  • suggested 68 % decrease in death but with a very low degree of certainty due to critical risk of bias

meta-analysis

CAP-China (Wang et al.) , 2020   NCT04257656 4 weeks ago

remdesevir vs. placebo low risk of bias

  • inconclusive results for: clinical improvement (HR); clinical improvement (day 14); clinical improvement (day 28); clinical improvement (day 7); death (28 days); AE leading to drug discontinuation; serious adverse events

meta-analysis

Follow-us

This project is self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons